Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JAB-3068 · 1 trial · 4 indications
Incidence of dose limiting toxicities (DLTs) . A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-3068 and JS001.
ORR is defined as the proportion of participants with complete response or partial response (CR+PR).
| Arm | Type | Description |
|---|---|---|
| JAB-3068+PD1 inhibitor Part1 | EXPERIMENTAL | JAB-3068+JS001 dose escalation |
| JAB-3068+PD1 inhibitor Part2 | EXPERIMENTAL | JAB-3068+JS001 dose expansion |
| Name | Type | Description |
|---|---|---|
| JAB-3068 | DRUG | JAB-3068 administrated orally as a tablet. |
| PD1 inhibitor | DRUG | JS001 administrated as an intravenous(IV) infusion. |
Inclusion Criteria: * Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses. * Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF). * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
JAB-3068 is an investigational small molecule drug being developed by AbbVie Inc. (ticker ABBV) for the treatment of advanced solid tumors. It is in Phase 1 clinical development and has been studied in a completed Phase 1 trial in China.
JAB-3068 is being studied for advanced solid tumors, including esophageal squamous cell carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. It is investigational and has not been approved for any indication.
JAB-3068 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program for this investigational oncology drug.
JAB-3068 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
JAB-3068 has been evaluated in one completed Phase 1 trial, NCT04721223, titled "JAB-3068 Activity in Adult Patients With Advanced Solid Tumors." The trial enrolled 12 adults aged 18 years and older in China and included patients with advanced solid tumors, esophageal squamous cell carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.